Literature DB >> 31926851

PD-1 Imposes Qualitative Control of Cellular Transcriptomes in Response to T Cell Activation.

Kenji Shimizu1, Daisuke Sugiura1, Il-Mi Okazaki1, Takumi Maruhashi1, Yujiro Takegami2, Chaoyang Cheng2, Soichi Ozaki2, Taku Okazaki3.   

Abstract

Targeted blockade of programmed cell death 1 (PD-1), an immune-checkpoint receptor that inhibits T cell activation, provides clinical benefits in various cancers. However, how PD-1 modulates gene expression in T cells remains enigmatic. Here we investigated how PD-1 affects transcriptome changes induced by T cell receptor (TCR) activation. Intriguingly, we identified a huge variance in PD-1 sensitivity among TCR-inducible genes. When we quantified the half maximal effective concentration (EC50) as the relationship between change in gene expression and TCR signal strength, we found that genes associated with survival and proliferation were efficiently expressed upon TCR activation and resistant to PD-1-mediated inhibition. Conversely, genes encoding cytokines and effector molecules were expressed less efficiently and sensitive to PD-1-mediated inhibition. We further demonstrated that transcription factor binding motifs and CpG frequency in the promoter region affect EC50 and thus the PD-1 sensitivity of genes. Our findings explain how PD-1, dependent on the TCR signal strength, calibrates cellular transcriptomes to shape functional properties of T cell populations.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CpG frequency; EC(50); PD-1; T cell receptor; cancer immunotherapy; co-receptor; gene expression; immunology; transcription factor; transcription start site

Mesh:

Substances:

Year:  2020        PMID: 31926851     DOI: 10.1016/j.molcel.2019.12.012

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  11 in total

1.  PD-1 preferentially inhibits the activation of low-affinity T cells.

Authors:  Kenji Shimizu; Daisuke Sugiura; Il-Mi Okazaki; Takumi Maruhashi; Tatsuya Takemoto; Taku Okazaki
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-31       Impact factor: 11.205

2.  PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity.

Authors:  Daisuke Sugiura; Il-Mi Okazaki; Takeo K Maeda; Takumi Maruhashi; Kenji Shimizu; Rieko Arakaki; Tatsuya Takemoto; Naozumi Ishimaru; Taku Okazaki
Journal:  Nat Immunol       Date:  2022-02-10       Impact factor: 31.250

Review 3.  Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets.

Authors:  Yungang Wang; Shouyan Deng; Jie Xu
Journal:  Cancer Biol Med       Date:  2020-08-15       Impact factor: 4.248

4.  Chromatin Priming Renders T Cell Tolerance-Associated Genes Sensitive to Activation below the Signaling Threshold for Immune Response Genes.

Authors:  Sarah L Bevington; Sky T H Ng; Graham J Britton; Peter Keane; David C Wraith; Peter N Cockerill
Journal:  Cell Rep       Date:  2020-06-09       Impact factor: 9.423

5.  Antigen and checkpoint receptor engagement recalibrates T cell receptor signal strength.

Authors:  Thomas A E Elliot; Emma K Jennings; David A J Lecky; Natasha Thawait; Adriana Flores-Langarica; Alastair Copland; Kendle M Maslowski; David C Wraith; David Bending
Journal:  Immunity       Date:  2021-09-16       Impact factor: 31.745

6.  Cyclic AMP Response Element Modulator-α Suppresses PD-1 Expression and Promotes Effector CD4+ T Cells in Psoriasis.

Authors:  Sigrun R Hofmann; Emil Carlsson; Franz Kapplusch; Ana L Carvalho; Triantafillos Liloglou; Felix Schulze; Susanne Abraham; Sarah Northey; Susanne Russ; Anna E A Surace; Nobuya Yoshida; George C Tsokos; Christian M Hedrich
Journal:  J Immunol       Date:  2021-06-16       Impact factor: 5.422

Review 7.  Immune checkpoint signaling and cancer immunotherapy.

Authors:  Xing He; Chenqi Xu
Journal:  Cell Res       Date:  2020-05-28       Impact factor: 25.617

Review 8.  Targeting immune checkpoints in hematological malignancies.

Authors:  Basit Salik; Mark J Smyth; Kyohei Nakamura
Journal:  J Hematol Oncol       Date:  2020-08-12       Impact factor: 17.388

9.  Nr4a1 and Nr4a3 Reporter Mice Are Differentially Sensitive to T Cell Receptor Signal Strength and Duration.

Authors:  Emma Jennings; Thomas A E Elliot; Natasha Thawait; Shivani Kanabar; Juan Carlos Yam-Puc; Masahiro Ono; Kai-Michael Toellner; David C Wraith; Graham Anderson; David Bending
Journal:  Cell Rep       Date:  2020-11-03       Impact factor: 9.423

Review 10.  Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches.

Authors:  Ji-Yoon Noh; Huiyun Seo; Jungwoon Lee; Haiyoung Jung
Journal:  Int J Mol Sci       Date:  2020-10-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.